Entera Bio Ltd. financial data

Symbol
ENTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 636 % -37.1%
Debt-to-equity 21.6 % +94.4%
Return On Equity -103 % -20.3%
Return On Assets -85 % -9.92%
Operating Margin -71.4 K % -1350%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.5 M shares +23.2%
Common Stock, Shares, Outstanding 35.5 M shares +23.3%
Entity Public Float 20.7 M USD -37.1%
Common Stock, Value, Issued 1 K USD
Weighted Average Number of Shares Outstanding, Basic 36.7 M shares +27.5%
Weighted Average Number of Shares Outstanding, Diluted 36.7 M shares +27.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 4.31 M USD -15.2%
General and Administrative Expense 4.46 M USD -30%
Operating Income (Loss) -8.74 M USD +23.3%
Nonoperating Income (Expense) 54 K USD -11.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.86 M USD +31.5%
Income Tax Expense (Benefit) 29 K USD -78.8%
Net Income (Loss) Attributable to Parent -8.72 M USD +24.1%
Earnings Per Share, Basic 0.28 USD/shares -30%
Earnings Per Share, Diluted 0.28 USD/shares -30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.19 M USD -14%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 39 K USD -94%
Assets, Current 9.75 M USD -14.3%
Deferred Income Tax Assets, Net 14 K USD -67.4%
Property, Plant and Equipment, Net 87 K USD -36%
Operating Lease, Right-of-Use Asset 381 K USD +694%
Assets 10.2 M USD -11.8%
Accounts Payable, Current 66 K USD -56%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 1.12 M USD -25%
Operating Lease, Liability, Noncurrent 224 K USD
Liabilities 1.38 M USD -9.83%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41 K USD 0%
Retained Earnings (Accumulated Deficit) -106 M USD -8.92%
Stockholders' Equity Attributable to Parent 8.86 M USD -12.1%
Liabilities and Equity 10.2 M USD -11.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.86 M USD -15.7%
Net Cash Provided by (Used in) Financing Activities 30 K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 140 M shares 0%
Common Stock, Shares, Issued 35.5 M shares +23.3%
Common Stock, Par or Stated Value Per Share 0 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.83 M USD -13.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.25 M USD -14%
Deferred Tax Assets, Valuation Allowance 19.5 M USD +10.3%
Deferred Tax Assets, Gross 19.5 M USD +10.2%
Operating Lease, Liability 390 K USD +329%
Depreciation 13 K USD -7.14%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 454 K USD
Operating Lease, Liability, Current 153 K USD +219%
Lessee, Operating Lease, Liability, to be Paid, Year Two 184 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 184 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure -12.5%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 64 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 86 K USD
Deferred Tax Assets, Operating Loss Carryforwards 17.4 M USD +13%
Lessee, Operating Lease, Liability, to be Paid, Year Four 83 K USD
Deferred Tax Assets, Net of Valuation Allowance 14 K USD -67.4%